Your Monday morning headlines: Police shooting in Minnesota sparks unrest; promising brain tumor treatment; Japan has its Masters champ. Get caught up.
Deadly Brain Tumor: Survival Extended by Oncolytic Virus Product medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
Combination increases complete response rate to 24% compared to chemotherapy alone
Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting.
Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery.
The primary endpoints of the study were pathological complete response (pCR), defined as no residual viable tumour in the resected lung specimen and the sampled lymph node after surgery and event-free survival (EFS).